CHMP negative opinion for Albrioza for the treatment of adults with amyotrophic lateral sclerosis.- Amylyx Pharma
Amylyx Pharmaceuticals, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the application for conditional marketing authorisation of AMX 0035 (sodium phenylbutyrate and ursodoxicoltaurine [also known as taurursodiol]), under the trade name Albrioza, for the treatment of adults with amyotrophic lateral sclerosis (ALS) in the European Union (EU).
Today’s update follows the Company’s May 2023 announcement that the CHMP was trending toward a negative opinion.
“We are confident in the strength of our CENTAUR trial data, which we believe meets the criteria for conditional approval. These data were also the basis of the full approval received from the FDA and the approval with conditions from Health Canada,” said Tammy Sarnelli, Global Head, Regulatory Affairs and Clinical Compliance at Amylyx. “We disagree with the CHMP’s opinion and will request a formal re-examination procedure of the current Marketing Authorisation Application (MAA).”
CENTAUR met its prespecified primary outcome, and AMX 0035 is the first ALS therapy to demonstrate, in the same trial, both a statistically significant benefit in function, as well as an observed benefit on overall survival in a longer-term post hoc analysis. AMX 0035 demonstrated a generally well-tolerated safety profile in the CENTAUR trial, with similar reported rates of adverse events and discontinuations in AMX 0035 and placebo groups during the 24-week randomized phase; however, gastrointestinal events occurred with greater frequency (greater than 2%) in the AMX 0035 group.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.